This paper analyses the promotion of medicines for human use that have already received marketing authorization, when the advertising is made before the resolution on pricing and inclusion in the Spanish National Health Service. This is an issue addressed by
Three of the most recognized experts on IP farma in Spain Ángel García Vidal, profesor de Derecho Mercantil de la Universidad de Santiago de Compostela y Consejero Académico de Gómez Acebo y Pombo, Kiko Carrión García de Parada, Abogado socio
Jorge Muñoz, Member of CEFI Board lead the debate on advanced therapies an biological medicinal products. Sol Ruíz, Jefe de División de Productos Biológicos, Terapias Avanzadas y Biotecnología de la Agencia Española de Medicamentos y Productos Sanitarios and Jordi Faus,
Interesting debate with Jesús Rubí, Adjunto a la Dirección de la Agencia Española de Protección de Datos, Amelia Martín Uranga, Responsable de la Plataforma de Medicamentos Innovadores de Farmaindustria and Lluis Alcover, Abogado de Faus y Moliner. Interestingf debate about main
On 15 October we had an interesting discussion on Observational Studies on Medications and patient support programmes in the new regulations that aroused a lot of interest. More than 90 people participated in the session with strong participation in questions
Superior Court of Justice of the Basque Country, Judicial Review Chamber, Judgment 246/2021 of 30 June resolved positively on a question widely debated in the sector: the possibility of advertising medicinal products that have been approved for sale but have
Considerations on the pricing system for medicinal products. Lourdes Fraguas Gadea Abuse of dominant position consisting on predatory prices. Spanish Competition Authority Astrazeneca inhalers Decision. Alfonso Gutiérrez Hernández and Alberto Pérez Hernández Public supply of medicines. Doctrine generated by the
The promotion of medicines for human use that have already receive marketing authorization, before the resolution on pricing and the inclusión in the Nacional Health System. Angel García Vidal and Irene Fernández Puyol Health Data 29 Playbook as a gvernance
Available for download. The promotion of medicines for human use that have already receive marketing authorization, before the resolution on pricing and the inclusión in the Nacional Health System. Angel García Vidal and Irene Fernández Puyol Health Data 29 Playbook
Rosa Romero Sánchez, Presidenta de la Comisión de Sanidad del Congreso de los Diputados and Katia Piñol, Presidenta de CEFI highlight the importance of holding this debate. Pharmaceutical sector and medicinal innovation are constantly searching for health improvement. We need
Alberto Dorrego. Abogado socio de Eversheds Sutherland claim for a specific regulación on public procurement for innovative medicines and vaccines. He also highlight the importance of price and hospital offers confidentiality Carme Briera, Cousel de Clifford Chance enter into a
Second week of the Pharmaceutical Law Course begin with one of the main issues for innovative medicines. Lead by Javier de Urquía Martí, member of CEFI Board we had as speakers: Jesús García Herrero, Jefe de la intervención de precios
Katia Piñol Torres, our President and Patricia Lacruz. Directora General de Cartera Común de Servicios del Sistema Nacional de Salud y Farmacia del Ministerio de Sanidad at the opening of the course. Nice speakers and more tan 180 attendees. This
With Javier Castrodeza, Ex Secretario General de Sanidad y Catedrático de Medicina Preventiva y Salud Pública, Lourdes Fraguas, Abogada of Cousel Herbert Smith Freehills Spain, César Hernández, Jefe del Departamento de Medicamentos de Uso Humano de la Agencia Española de
We cant think in a best way to end our 25th Pharmaceutical Law Course Aniversary . Moisés Ramírez, Patrono de CEFI together with Sergio Sinovas, Subdirector de Industria y Energía de la Dirección de Competencia de la CNMC, Borja Martínez
In this panel we are going to talk about promotion, digital aspects and compliance. As Speakers: Silvia Martínez, Patrono de CEFI, Jose Zamarriego Izquierdo, Director de la Unidad de la Supervisión Deontológica de Farmandustria, Alejandro González, Abogado de Hoyng Rokh
Section One. Current Affairs Medicine in the courts in 2020. Jordi Faus, Xavier Moliner, Eduard Rodellar, Santiago Tomás, Anna Gerbolés, Lluís Alcover, Laura Marquès, Juan Martínez, and Joan Carles Bailach Data protection in the COVID-19 pandemic (Part II). Jesús Rubí
Interruption of supply or the withdrawal of medicines from the market and competition rules. Henar González Durántez y Pilar Carrasco del Olmo 2021 versión of Pharmaceutical Industry Code of Best Practices. Teresa Paz-Ares Rodríguez, Beatriz Cocina Arrieta y Nuria
In light of the current COVID-19 health crisis, it is an apt moment to highlight the importance of intellectual property. Intellectual and industrial property, among others, allow us to turn ideas into concrete projects that create value, wealth, jobs, and
Commentary on the Royalty Pharma Ruling of the CJEU of 30 April 2020. Full text: Comunicaciones ENG oct 2020 pag This post is also available in: Spanish
The reference price system and annual reference price orders are intended to contribute to the sustainability of the SNS. They should also promote the right balance between innovative generic/biosimilar, competition and competitiveness in the pharmaceutical and health market. Price decisions
BIOSIMILAR AND GENERIC DRUGS With the document of statements, the CEFI Foundation analyses each of the specific measures proposed in the Plan in detail but, in general, it believes that in the draft of the plan, the basic principles of
CEFI, as a member of the Interministerial Commission to act against activities which infringe intellectual and industrial property rights, backs the institutional anti-counterfeiting campaign carried out by the Ministry of Industry, Trade and Tourism together with the Spanish Patent and
Farmaindustria has published an interesting decalogue on the value of brands. It is important to strengthen the role of brands as industrial property and business assets that strengthen competitiveness in the market and inform us about their attributes. They highlight
This post is also available in: Spanish
A foundation for promoting and supporting research and technological development, especially regarding the pharmaceutical industry
Nuestra entidad se encuentra adherida a Confianza Online (Asociación sin ánimo de lucro), inscrita en el Registro Nacional de Asociaciones Grupo 1, Sección 1, número nacional 594400, CIF G85804011, Calle Carrera de San Jerónimo, 18 28014 Madrid (España).. Para más información: (confianzaonline.es).
